Theratechnologies Announces Dosing of First Patient in Updat

Milestone for Company’s lead peptide-drug conjugate candidate follows FDA acceptance of protocol amendment for Phase 1 study on June 2, 2023

Related Keywords

United States , Montreal , Quebec , Canada , American , Julie Schneiderman , Ira Winer , Christian Marsolais , Philippe Dubuc , Drug Administration , Twitter , American Society Of Clinical Oncology , Milestone For Company , Linkedin , Karmanos Cancer Center , Communications Corporate Affairs , Theratechnologies Inc , Senior Vice President , Chief Medical Officer , Gynecologic Oncology , American Society , Sudocetaxel Zendusortide , Fast Track , Forward Looking Statements , Looking Statements , Annual Information Form , Vice President , Chief Financial , National ,